Clinical Trial Update: Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age [Phase 3]

View source ↗

Summary

Phase 3 trial update for a pneumococcal conjugate vaccine in healthy infants aged 6 to 8 weeks, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections
• Rotavirus Infection

Drugs mentioned

• Synflorix (10-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Rotavirus | Phase 3 | Status: COMPLETED | Results posted: 2009-07-24